These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26822262)

  • 1. Successful switch from insulin to oral sulfonylurea therapy in HNF1A-MODY Tunisian patient with the P291fsinsC mutation.
    Khelifa SB; Dendana A; Barboura I; Khochtali I; Chahed H; Ferchichi S; Miled A
    Diabetes Res Clin Pract; 2016 May; 115():133-6. PubMed ID: 26822262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of young patients with HNF1A mutations (HNF1A-MODY).
    Raile K; Schober E; Konrad K; Thon A; Grulich-Henn J; Meissner T; Wölfle J; Scheuing N; Holl RW;
    Diabet Med; 2015 Apr; 32(4):526-30. PubMed ID: 25483937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis of hepatic nuclear factor 1A monogenic diabetes mellitus (HNF1A-MODY) impacts antihyperglycemic treatment.
    Schnedl WJ; Holasek SJ; Schenk M; Enko D; Mangge H
    Wien Klin Wochenschr; 2021 Mar; 133(5-6):241-244. PubMed ID: 33245425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young.
    Ellard S; Colclough K
    Hum Mutat; 2006 Sep; 27(9):854-69. PubMed ID: 16917892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model.
    Urbanova J; Andel M; Potockova J; Klima J; Macek J; Ptacek P; Mat'oska V; Kumstyrova T; Heneberg P
    Curr Pharm Des; 2015; 21(39):5736-48. PubMed ID: 26446475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort.
    Bacon S; Kyithar MP; Rizvi SR; Donnelly E; McCarthy A; Burke M; Colclough K; Ellard S; Byrne MM
    Diabet Med; 2016 Jul; 33(7):976-84. PubMed ID: 26479152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Digenic heterozygous HNF1A and HNF4A mutations in two siblings with childhood-onset diabetes.
    Shankar RK; Ellard S; Standiford D; Pihoker C; Gilliam LK; Hattersley A; Dolan LM
    Pediatr Diabetes; 2013 Nov; 14(7):535-8. PubMed ID: 23551881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homozygous Hypomorphic
    Misra S; Hassanali N; Bennett AJ; Juszczak A; Caswell R; Colclough K; Valabhji J; Ellard S; Oliver NS; Gloyn AL
    Diabetes Care; 2020 Apr; 43(4):909-912. PubMed ID: 32001615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maturity onset diabetes of the young: Seek and you will find.
    Heuvel-Borsboom H; de Valk HW; Losekoot M; Westerink J
    Neth J Med; 2016 Jun; 74(5):193-200. PubMed ID: 27323672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation of HNF1A variants in paediatric diabetes in Norway using functional and clinical investigations to unmask phenotype and monogenic diabetes.
    Svalastoga P; Kaci A; Molnes J; Solheim MH; Johansson BB; Krogvold L; Skrivarhaug T; Valen E; Johansson S; Molven A; Sagen JV; Søfteland E; Bjørkhaug L; Tjora E; Aukrust I; Njølstad PR
    Diabetologia; 2023 Dec; 66(12):2226-2237. PubMed ID: 37798422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three unreported glucokinase (GCK) missense mutations detected in the screening of thirty-two Brazilian kindreds for GCK and HNF1A-MODY.
    Weinert LS; Silveiro SP; Giuffrida FM; Cunha VT; Bulcão C; Calliari LE; Della Manna T; Kunii IS; Dotto RP; Dias-da-Silva MR; Reis AF
    Diabetes Res Clin Pract; 2014 Nov; 106(2):e44-8. PubMed ID: 25174781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A family with a novel termination mutation in hepatic nuclear factor 1α in maturity-onset diabetes of the young type 3 which is unresponsive to sulphonylurea therapy.
    Demol S; Lebenthal Y; Bar-Meisels M; Phillip M; Gat-Yablonski G; Gozlan Y
    Horm Res Paediatr; 2014; 81(4):280-4. PubMed ID: 24642958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MODY in Ukraine: genes, clinical phenotypes and treatment.
    Globa E; Zelinska N; Elblova L; Dusatkova P; Cinek O; Lebl J; Colclough K; Ellard S; Pruhova S
    J Pediatr Endocrinol Metab; 2017 Oct; 30(10):1095-1103. PubMed ID: 28862987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monogenic diabetes: the treatment options.
    Owen KR
    Diabet Med; 2015 Apr; 32(4):429-30. PubMed ID: 25773279
    [No Abstract]   [Full Text] [Related]  

  • 15. Maturity Onset Diabetes of the Young (MODY) in Tunisia: Low frequencies of GCK and HNF1A mutations.
    Ben Khelifa S; Martinez R; Dandana A; Khochtali I; Ferchichi S; Castaño L
    Gene; 2018 Apr; 651():44-48. PubMed ID: 29408271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic ketoacidosis in the setting of HNF1A-maturity onset diabetes of the young.
    Egan AM; Cunningham A; Jafar-Mohammadi B; Dunne FP
    BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25837654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of new mutation in maturity-onset diabetes of the young type 3 (MODY 3) responsive to a low dose of sulphonylurea.
    Jesić MD; Sajić S; Jesić MM; Maringa M; Micić D; Necić S
    Diabetes Res Clin Pract; 2008 Jul; 81(1):e1-3. PubMed ID: 18433912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life assessment in patients with HNF1A-MODY and GCK-MODY.
    Szopa M; Matejko B; Ucieklak D; Uchman A; Hohendorff J; Mrozińska S; Głodzik W; Zapała B; Płatek T; Solecka I; Sani CM; Małecki MT
    Endocrine; 2019 May; 64(2):246-253. PubMed ID: 30421137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of HNF1A (MODY3) mutations in a Norwegian population (the HUNT2 Study).
    Eide SA; Raeder H; Johansson S; Midthjell K; Søvik O; Njølstad PR; Molven A
    Diabet Med; 2008 Jul; 25(7):775-81. PubMed ID: 18513305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mody-3: novel HNF1A mutation and the utility of glucagon-like peptide (GLP)-1 receptor agonist therapy.
    Docena MK; Faiman C; Stanley CM; Pantalone KM
    Endocr Pract; 2014 Feb; 20(2):107-11. PubMed ID: 24014008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.